These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 32399639)

  • 1. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
    Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
    Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
    BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSMA-positive nodal recurrence in prostate cancer : Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis.
    Schmidt-Hegemann NS; Buchner A; Eze C; Rogowski P; Schaefer C; Ilhan H; Li M; Fendler WP; Bartenstein P; Ganswindt U; Stief C; Belka C; Kretschmer A
    Strahlenther Onkol; 2020 Jul; 196(7):637-646. PubMed ID: 32211942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
    Harsini S; Martineau P; Plaha S; Saprunoff H; Chen C; Bishop J; Tyldesley S; Wilson D; Bénard F
    Cancer Imaging; 2024 Aug; 24(1):117. PubMed ID: 39210431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Progression After
    Soldatov A; von Klot CAJ; Walacides D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; Christiansen H; Henkenberens C
    Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):95-104. PubMed ID: 30201438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes of metastasis-directed treatment using
    Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
    Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer.
    Stefan A Koerber ; Katharina Sprute ; Clemens Kratochwil ; Erik Winter ; Matthias F Haefner ; Sonja Katayama ; Ingmar Schlampp ; Klaus Herfarth ; Klaus Kopka ; Ali Afshar-Oromieh ; Stefanie Zschaebitz ; Tim Holland-Letz ; Peter L Choyke ; Dirk Jaeger ; Markus Hohenfellner ; Uwe Haberkorn ; Juergen Debus ; Frederik L Giesel
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):143-151. PubMed ID: 32405735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy.
    Harsini S; Wilson D; Saprunoff H; Allan H; Gleave M; Goldenberg L; Chi KN; Kim-Sing C; Tyldesley S; Bénard F
    Cancer Imaging; 2023 Mar; 23(1):27. PubMed ID: 36932416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression-free survival in patients with
    Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM
    Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Artigas C; Flamen P; Charlier F; Levillain H; Wimana Z; Diamand R; Albisinni S; Gil T; Velthoven RV; Peltier A; Gestel DV; Roumeguere T; Otte FX
    World J Urol; 2019 Aug; 37(8):1535-1542. PubMed ID: 30824985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer.
    Henkenberens C; Derlin T; Bengel F; Ross TL; Kuczyk MA; Giordano FA; Sarria GR; Schmeel LC; Christiansen H; von Klot CAJ
    Front Oncol; 2021; 11():664225. PubMed ID: 33954116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging.
    Onal C; Guler OC; Erpolat P; Hurmuz P; Sutera P; Deek MP; Elmali A; Yilmaz MT; Koken UH; Yavuz M; Ozyigit G; Tran PT
    Clin Nucl Med; 2024 Aug; 49(8):e383-e389. PubMed ID: 38847441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study.
    Janbain A; Farolfi A; Guenegou-Arnoux A; Romengas L; Scharl S; Fanti S; Serani F; Peeken JC; Katsahian S; Strouthos I; Ferentinos K; Koerber SA; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SK; Grosu AL; Ceci F; Henkenberens C; Kroeze SG; Guckenberger M; Belka C; Bartenstein P; Hruby G; Emmett L; Omerieh AA; Schmidt-Hegemann NS; Mose L; Aebersold DM; Zamboglou C; Wiegel T; Shelan M
    JMIR Cancer; 2024 Sep; 10():e60323. PubMed ID: 39303279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
    Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
    Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years.
    Shakespeare TP; Eggert E; Wood M; Westhuyzen J; Turnbull K; Rutherford N; Aherne N
    Radiother Oncol; 2019 Dec; 141():188-191. PubMed ID: 31668514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.